Involvement of cysteinyl leukotriene receptor 1 in Aβ1–42-induced neurotoxicity in vitro and in vivo

Tang, Shuming; Hong, Hao; Chen, Lan; Mei, Zhen-lin; Ji, Miao-jin; Xiang, Guoqing; Li, Ning; Ji, Hui

doi:10.1016/j.neurobiolaging.2013.09.036

Cited by 57 publications

(34 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was carried out as described previously (Tang et al, 2014). Mice were individually trained in a circular pool (120 cm diameter, 50 cm height) filled up to a depth of 30 cm with water maintained at 25°C.…”

Section: Morris Water Maze (Mwm) Testmentioning

confidence: 99%

Antidiabetic drugs restore abnormal transport of amyloid-β across the blood–brain barrier and memory impairment in db / db mice

et al. 2016

Self Cite

View full text Add to dashboard Cite

Section: Morris Water Maze (Mwm) Testmentioning

confidence: 99%

Antidiabetic drugs restore abnormal transport of amyloid-β across the blood–brain barrier and memory impairment in db / db mice

et al. 2016

Self Cite

View full text Add to dashboard Cite

“…On day 3, day 4 and day 5, the hidden‐platform test was performed to determine the retention of memory and assess the spatial learning. The probe trial was conducted on day 6 . The swimming speed, latency, time spent in the target quadrant and the number of target crossings were recorded and handled by the analysis‐management system (Viewer Tracking Software, Ji Liang Instruments, Shanghai, China).…”

Section: Methodsmentioning

confidence: 99%

Neuroprotective effect of mogrol against Aβ1–42-induced memory impairment neuroinflammation and apoptosis in mice

Chen

Liu

Meng

et al. 2018

Journal of Pharmacy and Pharmacology

Self Cite

View full text Add to dashboard Cite

Objectives Cognitive impairment is the main character of Alzheimer's disease (AD). This study mainly focused on whether mogrol, a tetracyclic triterpenoids compound of Siraitia grosvenorii Swingle, can ameliorate the memory impairment induced by Aβ1–42. Methods Memory impairment mice model was made by stereotactic intra‐hippocampal microinjection of Aβ1–42 (410 pm/mouse). Mogrol (20, 40, 80 mg/kg) was given to mice by intragastric administration at 3 days after Aβ1–42 injection for totally 3 weeks. Morris water maze test and Y‐maze test were operated to evaluate the therapeutic effect of morgrol on Aβ1–42‐induced memory impairments. Immunohistochemical analyses and Hoechst 33258 assay were used to evaluate effect of morgrol on Aβ1–42‐induced microglia overactivation and apoptotic response in hippocampus of mice. Western blotting assay was used to evaluate effect of mogrol on the Aβ1–42‐activated NF‐κB signaling. Key findings Mogrol could significantly alleviate Aβ1–42‐induced memory impairments, inhibit Aβ1–42‐induced microglia overactivation and prevent Aβ1–42‐triggered apoptotic response in the hippocampus. Mogrol also could suppress Aβ1–42‐activated NF‐κB signaling, reduce the production of proinflammatory cytokines. Conclusions This study suggested that mogrol would ameliorate the memory impairment induced by Aβ1–42, which is involved in anti‐inflammation and anti‐apoptosis in the brain.

show abstract

“…In primary culture of mouse neurons, A β 1–42 markedly increased CysLTR-1 expression, which was associated with cytotoxicity, inflammatory, and apoptotic responses. Incubation with pranlukast and montelukast reversed the upregulation of A β 1–42 -induced CysLTR-1 and NF-kB p65 and activated caspase-3 expression and the downregulation of Bcl-2 [130,131]. In bilateral i.c.v.…”

Section: Cerebral Localization Of Cyslt Receptorsmentioning

confidence: 99%

Cysteinyl Leukotrienes as Potential Pharmacological Targets for Cerebral Diseases

Gelosa

Colazzo

Tremoli

et al. 2017

Mediators of Inflammation

View full text Add to dashboard Cite

Cysteinyl leukotrienes (CysLTs) are potent lipid mediators widely known for their actions in asthma and in allergic rhinitis. Accumulating data highlights their involvement in a broader range of inflammation-associated diseases such as cancer, atopic dermatitis, rheumatoid arthritis, and cardiovascular diseases. The reported elevated levels of CysLTs in acute and chronic brain lesions, the association between the genetic polymorphisms in the LTs biosynthesis pathways and the risk of cerebral pathological events, and the evidence from animal models link also CysLTs and brain diseases. This review will give an overview of how far research has gone into the evaluation of the role of CysLTs in the most prevalent neurodegenerative disorders (ischemia, Alzheimer's and Parkinson's diseases, multiple sclerosis/experimental autoimmune encephalomyelitis, and epilepsy) in order to understand the underlying mechanism by which they might be central in the disease progression.

show abstract

Involvement of cysteinyl leukotriene receptor 1 in Aβ1–42-induced neurotoxicity in vitro and in vivo

Cited by 57 publications

References 45 publications

Antidiabetic drugs restore abnormal transport of amyloid-β across the blood–brain barrier and memory impairment in db / db mice

Antidiabetic drugs restore abnormal transport of amyloid-β across the blood–brain barrier and memory impairment in db / db mice

Neuroprotective effect of mogrol against Aβ1–42-induced memory impairment neuroinflammation and apoptosis in mice

Cysteinyl Leukotrienes as Potential Pharmacological Targets for Cerebral Diseases

Contact Info

Product

Resources

About